These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

809 related items for PubMed ID: 26053183

  • 1. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S, Huang L, Chen CM, Shao ZM.
    Oncotarget; 2015 Jul 20; 6(20):18174-82. PubMed ID: 26053183
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX, Qin QH, Yang WP, Mo QG, Wei CY.
    Int J Clin Exp Pathol; 2014 Jul 20; 7(10):6862-70. PubMed ID: 25400769
    [Abstract] [Full Text] [Related]

  • 3. Clinical and pathological response to neoadjuvant chemotherapy based on primary tumor reduction is correlated to survival in hormone receptor-positive but not hormone receptor-negative locally advanced breast cancer.
    Chen S, Liu Y, Ouyang QW, Huang L, Luo RC, Shao ZM.
    Ann Surg Oncol; 2015 Jan 20; 22(1):32-9. PubMed ID: 25012266
    [Abstract] [Full Text] [Related]

  • 4. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
    Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M.
    Eur J Surg Oncol; 2013 Mar 20; 39(3):260-5. PubMed ID: 23313014
    [Abstract] [Full Text] [Related]

  • 5. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L, De Matteis E, Cirilli C, Marcheselli L, Proietto M, Federico M.
    Tumori; 2012 Nov 20; 98(6):743-50. PubMed ID: 23389361
    [Abstract] [Full Text] [Related]

  • 6. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.
    Breast Cancer Res Treat; 2010 Nov 20; 124(2):387-91. PubMed ID: 20824324
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
    Matsubara N, Mukai H, Fujii S, Wada N.
    Breast Cancer Res Treat; 2013 Jan 20; 137(1):203-12. PubMed ID: 23184081
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.
    J BUON; 2013 Jan 20; 18(2):366-71. PubMed ID: 23818347
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.
    Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M.
    Ann Oncol; 2015 Feb 20; 26(2):307-13. PubMed ID: 25411418
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X, Jiang YZ, Chen S, Yu KD, Shao ZM, Di GH.
    Oncotarget; 2015 Apr 20; 6(11):9600-11. PubMed ID: 25826079
    [Abstract] [Full Text] [Related]

  • 17. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A, Yagi T, Yanai A, Miyagawa Y, Enomoto Y, Murase K, Imamura M, Takatsuka Y, Sakita I, Hatada T, Miyoshi Y.
    Clin Breast Cancer; 2015 Jun 20; 15(3):204-11. PubMed ID: 25600243
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
    Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM.
    Ann Surg Oncol; 2012 Sep 20; 19(9):3002-11. PubMed ID: 22437200
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.